

Table 7.6g
Immunosuppression Use for Maintenance Between Discharge
and One Year Following Transplantation, 1997 to 2006
Recipients with Pancreas After Kidney (PAK) Transplants

	Year of Transplant									
	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
Transplants	130	156	220	304	305	375	344	420	343	293
Tx with Follow-up Immunosuppression Info	89	110	167	219	245	272	258	319	255	219
Corticosteroids										
Any in Category	100.0%	100.0%	100.0%	99.1%	98.8%	94.5%	78.7%	73.4%	73.3%	71.2%
Steroids	100.0%	100.0%	100.0%	99.1%	98.8%	94.5%	78.7%	73.4%	73.3%	71.2%
Cyclosporine										
Any in Category	21.3%	32.7%	14.4%	16.0%	15.1%	15.4%	11.2%	8.2%	6.7%	6.8%
Sandimmune	4.5%	5.5%	2.4%	3.2%	0.8%	1.1%	0.0%	0.3%	0.0%	0.5%
Neoral	16.9%	27.3%	12.0%	11.9%	12.7%	12.1%	9.3%	5.0%	6.3%	6.4%
Gengraf	0.0%	0.0%	0.0%	0.9%	0.8%	2.2%	1.6%	2.8%	0.4%	0.0%
Eon	0.0%	0.0%	0.0%	0.0%	0.8%	0.0%	0.4%	0.0%	0.0%	0.0%
Tacrolimus										
Any in Category	88.8%	76.4%	91.0%	91.8%	91.8%	87.1%	82.9%	87.1%	92.5%	91.8%
Tacrolimus	88.8%	76.4%	91.0%	91.8%	91.8%	87.1%	82.9%	87.1%	92.5%	91.8%
Antimetabolites										
Any in Category	100.0%	99.1%	95.2%	84.5%	80.4%	80.5%	84.9%	82.1%	89.0%	87.2%
Mycophenolate Mofetil	89.9%	89.1%	86.2%	78.5%	78.0%	78.3%	81.0%	79.0%	82.7%	75.3%
Mycophenolate Sodium	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	2.2%	4.3%	8.7%
Azathioprine	10.1%	10.0%	9.0%	5.9%	2.4%	2.2%	3.5%	0.3%	2.0%	1.8%
Leflunomide	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.4%	0.6%	0.0%	1.4%
Cytosan	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
mTOR Inhibitors										
Any in Category	0.0%	0.9%	7.2%	24.7%	30.6%	31.6%	27.5%	25.7%	19.2%	17.4%
Sirolimus	0.0%	0.9%	7.2%	24.7%	30.6%	31.6%	27.5%	25.7%	19.2%	17.4%
Everolimus	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Percentages are calculated based on the total number of patients with any immunosuppression use between discharge and one year following transplantation.
 Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.